Mechanical Properties of Peripheral and Accessory Respiratory Muscles in Chronic Obstructive Pulmonary Disease Patients
Istanbul Medipol University Hospital
66 participants
Jan 20, 2024
OBSERVATIONAL
Conditions
Summary
The biomechanical properties of accessory respiratory muscles and peripheral muscles of COPD and healthy subjects will be measured and compared with the MyotonPro device.
Eligibility
Inclusion Criteria6
- Being diagnosed with group C and D COPD according to GOLD staging
- Having been using the same medications for the last 4 weeks
- No additional comorbid diseases of the orthopedic, neurological or cardiac system
- Being over 18 years of age
- Not having any diagnosed chronic disease
- Not being a smoker
Exclusion Criteria5
- Presence of another respiratory system disease other than COPD
- Patients who have had an acute COPD exacerbation in the last 4 weeks
- Patients experiencing COPD exacerbations during the study protocol
- Presence of fatty tissue at the measurement points, which may impair the measurement quality.
- Have already participated in another clinical trial within the last 30 days that may affect the results of the study.
Interventions
All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06201403